Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03516604
Other study ID # PF04995274 Study 1 RESTAND
Secondary ID MR/P012604/1
Status Completed
Phase Phase 1
First received
Last updated
Start date May 16, 2018
Est. completion date July 29, 2022

Study information

Verified date October 2022
Source University of Oxford
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will test whether seven days administration of a serotonin receptor subtype 4 (5HT4) agonist called PF-04995274 has positive effects on cognition, emotional processing and neural activity in unmedicated depressed patients compared to placebo. The study will also include a group of patients randomised to seven days administration of citalopram (20 mg), which is a standard treatment for depression.


Description:

This study uses a double-blind, placebo-controlled, randomised between-groups design to test if administration of a serotonin receptor subtype 4 (5HT4) agonist called PF-04995274 has positive effects on emotional processing and neural activity in unmedicated depressed patients. Participants are patients who fulfill criteria for current episode of Major Depressive Disorder (MDD), and they will be randomised to receive 7 days treatment with either PF-04995274 (15 mg daily), citalopram (20 mg daily) or a matched placebo. Participants will come for a Screening Visit, a First Dose Visit, Research Visit One (including MRI scan) and Research Visit Two (including measures of emotional processing and non-emotion cognition).


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date July 29, 2022
Est. primary completion date July 29, 2022
Accepts healthy volunteers No
Gender All
Age group 16 Years to 65 Years
Eligibility Inclusion Criteria: - Male or female - Aged 18-65 years; - Willing and able to give informed consent for participation in the study; - Sufficiently fluent English to understand and complete the tasks; - Registered with a GP and consents to GP being informed of participation in study; - Meet DSM-V criteria for current Major Depressive Disorder [as determined by the Structured Clinical interview for DSM-V (SCID)]; - Participant must have received no drug or face-to-face psychological treatment for the current episode of depression/ in the previous six weeks; - Participants engaging in sex with a risk of pregnancy must agree to use a highly effective method of contraception from Screening Visit until 30 days after receiving study medication treatment, female participants must not breastfeed, and male participants must not donate sperm. Exclusion Criteria: - History of or current DSM-V bipolar disorder, schizophrenia or eating disorders. Participants who fulfil current criteria for other comorbid disorders may still be entered into the study, if, in the opinion of the Investigator, the psychiatric diagnosis will not compromise safety or affect data quality; - First-degree relative with a diagnosis of Bipolar Disorder type 1; - Current usage of psychotropic medication; - Failure to respond to antidepressant medication in current episode; - Electroconvulsive therapy for the treatment of the current episode of depression; - Participants undergoing any form of face-to-face structured psychological treatment during the study; - Clinically significant abnormal values for liver function tests, clinical chemistry, urine drug screen, blood pressure measurement and ECG. A participant with a clinical abnormality or parameters outside the reference range for the population being studied may be included only if the Investigator considers that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures; - History of stimulant abuse (lifetime; e.g. amphetamine, cocaine), or of alcohol abuse within one year or of alcohol dependence within the lifetime; - History of, or current medical conditions which in the opinion of the investigator may interfere with the safety of the participant or the scientific integrity of the study, including epilepsy/seizures, brain injury, severe hepatic or renal disease, severe gastro-intestinal problems, Central Nervous System (CNS) tumors, severe neurological problems (like Parkinson's; blackouts requiring hospitalisation); - Medical conditions that may alter the hemodynamic parameters underlying the BOLD signal (e.g., inadequately treated hypertension, diabetes mellitus); - Clinically significant risk of suicide; - Current pregnancy (as determined by urine pregnancy test taken during Screening and First Dose Visits), breastfeeding or planning a pregnancy during the course of the study; - Participant not willing to use a suitable method of contraception for 30 days after receiving study drug treatment; - Any contraindication to MRI scanning (e.g. metal objects in body, pacemakers, significant claustrophobia, pregnancy); - Participants with Body Mass Index (BMI) outside the 18 to 36 kg/m2 range at the Screening Visit. - Night-shift working or recent travel involving significant change of timezones; - Excessive caffeine consumption, i.e., consumption higher than 8 cups of standard caffeinated drinks (tea, instant coffee) or higher than 6 cups of stronger coffee or other drinks containing methylxanthines such as coca cola or Red Bull per day; - Participation in a psychological or medical study involving the use of medication within the last 3 months; - Previous participation in a study using the same, or similar, emotional processing tasks; - Smoker > 10 cigarettes per day or similar levels of tobacco consumption in other forms. - Participant received prescribed medication within 28 days prior to Visit 2 (apart from the contraceptive pill). Participants who have taken prescription medication may still be entered into the study, if, in the opinion of the Investigator, the medication received will not interfere with the study procedures or compromise safety; - Participant received non-prescription medication, including supplements such as vitamins and herbal supplements within 48 hours prior to Visit 2 (apart from paracetamol). Participants who have taken non-prescription medication may still be entered into the study, if, in the opinion of the Investigator, the medication received will not interfere with the study procedures or compromise safety; - Participant with a known hypersensitivity to PF-04995274, citalopram or any other serotonergic agents; - Participant with planned medical treatment within the study period that might interfere with the study procedures; - Participant who is unlikely to comply with the clinical study protocol or is unsuitable for any other reason, in the opinion of the Investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PF-04995274
PF-04995274 tablets
Citalopram
Citalopram capsule
Placebo Oral Tablet
Placebo tablet, identical to PF-04995274 tablet
Placebo oral capsule
Placebo capsule, identical to citalopram capsule

Locations

Country Name City State
United Kingdom University of Oxford Oxford Oxfordshire

Sponsors (3)

Lead Sponsor Collaborator
University of Oxford Medical Research Council, Pfizer

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hippocampal BOLD signal during fMRI Hippocampal and parahippocampal BOLD signal during familiar novel task - participants are presented with either previously trained (familiar) or novel images and are asked to identify whether animal or non-animal with a button press Completed on Day 6-8
Primary BOLD signal during fMRI Amygdala, anterior cingulate, prefrontal and orbitofrontal BOLD signal during emotional faces task - participants are presented with pictures of facial expressions of emotions and are asked to identify the gender of each face via button press. Completed on Day 6-8
Secondary Auditory Verbal Learning Task (AVLT) Accuracy of recall on the auditory verbal learning task Completed on Day 7-9
Secondary Emotional Memory Task Recall and recognition of affective words displayed earlier in the testing session is tested Completed on Day 7-9
Secondary Facial Expression Recognition Task (FERT) Facial expressions of basic emotions (happiness, fear, anger, disgust, sadness, surprise) are displayed on the screen and participants are asked to correctly classify them. Each emotion is presented at different intensity levels. Responses are made via a button-press and accuracy and reaction time are recorded. Completed on Day 7-9
Secondary Probabilistic Instrumental Learning Task (PILT) Participants have to learn which shapes are associated with wins and losses and sensitivity to reward is assessed. Completed on Day 7-9
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05114824 - Acceptability and Feasibility of an 8-week Online Mindfulness-Based Cognitive Therapy Program Among Undergraduate Students N/A
Not yet recruiting NCT05958940 - BioClock: Bright Light Therapy for Depressive Disorders N/A
Completed NCT03556735 - Pulsed Electro Magnetic Fields (PEMF) in Depression N/A
Completed NCT04916548 - Repeated Neurocognitive Measurements in Depressed Patients Phase 1/Phase 2
Recruiting NCT05767073 - LIVES: Personalized Lifestyle Intervention for Patients With Depression N/A
Completed NCT06094907 - Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression Phase 2
Completed NCT04121091 - Pramipexole to Target "Anhedonic Depression" Phase 2
Recruiting NCT06092411 - Effects of CBT and BLT in Youth With Unipolar Depression and Evening Chronotype N/A
Enrolling by invitation NCT03847688 - Machine Learning to Predict Clinical Response to TMS
Completed NCT02945735 - Gaze Contingent Feedback in Major Depressive Disorder (MDD) N/A
Recruiting NCT06139159 - CRISOL Mente: A Multilevel Community Intervention to Reduce Mental Health Disparities Among Latinos N/A
Recruiting NCT05011864 - Integrated Tele-Behavioral Activation and Fall Prevention for Low-income Homebound Seniors With Depression N/A
Terminated NCT03537547 - Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder Phase 4
Completed NCT03515733 - PF-04995274 and Emotional Processing in Treatment Resistant Depression Phase 1
Not yet recruiting NCT05991232 - Repeated Neurocognitive Measurements in Depressed Patients Phase 1/Phase 2
Completed NCT03538275 - Chronobiology and Depression: Circadian Analytics as a Biomarker for Depressive Subtypes
Active, not recruiting NCT03096886 - Novel Neural Circuit Biomarkers of Major Depression Response to CCBT N/A
Not yet recruiting NCT06462196 - Natural History of Depression, Bipolar Disorder and Suicide Risk
Completed NCT01874951 - Low-Dose Naltrexone for Depression Relapse and Recurrence Phase 2
Completed NCT03906175 - Whole-body Hyperthermia for Mild to Moderate Depressive Disorder N/A